Reda (@RedaKeddar) header
Reda (@RedaKeddar) profile picture

Senior Scientist @AstraZeneca interested in understanding mechanisms of resistance to cancer immunotherapy.

Cambridge, England
Joined October 2015
New #JITC article: "Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapy" jitc.bmj.com/content/14/5/e0… @kalender_atak @imartincorena @AdamJSchoenfeld @AstraZeneca
11
33
1,857
Only few places left! 🧐 Next Cam Comp Onco meeting ⏲️ March 15th, 3-6 pm 🛖 hosted by AZ at the DISC 📢 @OMRueda @AppleTreeWoman @RedaKeddar ❗️❗️Register by march 10th❗️❗️ forms.office.com/e/iRW1Eak3t…
5
3
14
4,790
Miriam Merad, MD, PhD, Elected to the National Academy of Medicine for Seminal Work in Immunology and Cell Biology | Mount Sinai - New York shar.es/agmF0C @IcahnMountSinai @SinaiImmunol @theNAMedicine
2
7
52
2,546
Thrilled to begin my tenure as the new president of @iuis_online! We are working toward demystifying immunology research, fostering global collaborations & bringing new immunotherapies to patients everywhere 🤝 Read more here: iuis.org/about/who-we-are/ed…
21
40
4
377
38,043
'Mechanisms driving the immunoregulatory function of cancer cells' nature.com/articles/s41568-0…
45
165
13,865
Very proud to be inducted today along incredible scientists @theNASciences and very grateful to many people and institutions that led me here. Starting with my Med school mentors in Algiers including my parents who taught me intellectual engagement , discipline & rigor (1/x)
103
32
8
759
Can we break the glass ceiling of PD1/PDL1 inhibition? In the #COAST phase 2 trial, stage III NSCLC pts were randomized after CT/RT to durvalumab +/- oleclumab (anti-CD73) or monalizumab (anti-NKG2A). Both study arms showed doubled ORR & prolonged PFS. ascopubs.org/doi/abs/10.1200…
2
30
4
98
Dressler, Bortolomeazzi,@RedaKeddar, Misetic, Sartini, @AmeAchaSag, Montorsi, @fcicca & co present the 6th update of the Network of Cancer Genes database. It contains 3355 well-known or predicted cancer drivers, but shows there are still unknown drivers genomebiology.biomedcentral.…
1
5
1
12
Reda retweeted
In patients with microsatellite-unstable colorectal tumors, pembrolizumab led to longer progression-free survival and was less toxic than standard care.

34
6
127
Replying to @RedaKeddar
@RedaKeddar from our lab presenting the results of out profile of immune and cancer cells in response to immunotherapy @TheCrick @KCLcancer_pharm @ITN_CONTRA @CR_UK #CrickCancerConf
1
9
KEYNOTE-158 study out in Lancet Oncology, Pembrolizumab for TMB>10- most data time date we have seen since FDA approval, key aspects include tumor types studied thelancet.com/journals/lanon…
4
30
4
86
Still a few days to apply and work with us @TheCrick @KCLcancer_pharm @CRUKresearch. Details below 👇 Pls spread the word and RT. 🙏🏽 jobs.kcl.ac.uk/gb/en/job/004…
CRI scientist Dr. Hiroyoshi Nishikawa of Japan National Cancer Center revealed how a single mutation can reprogram the tumor microenvironment in a way that favors the metabolism and activity of immune-suppressing Tregs. cell.com/immunity/fulltext/S…
1
11
1
30
Interested to see how the forthcoming data behind the ‘TMB > 10 in all cancer types’ approval addresses a few key issues, having spent a long time thinking about this general topic - some thoughts to follow: [1/n]
5
43
17
103
New issue online! cell.com/immunity/issue?pii=… Cover from @MartinGuilliams, Thierry, Bonnardel, & @BajenoffL on their review of the #macrophage niche. Art by Sigrid Knemeyer & Matt Crotts (SciStories). Includes a trio of Reviews on interactions of immune & non-immune cells in tissues!
7
33
10
111